{"filing":{"accession_number":"0001104659-26-074558","cik":"0001434868","ticker":"ESPR","company_name":"Esperion Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"tm2617356d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434868/000110465926074558/tm2617356d2_8k.htm"},"events":[{"id":11281,"run_id":9899,"accession_number":"0001104659-26-074558","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"The filing discloses that the HSR waiting period for the previously announced merger between Esperion and ArchiMed SAS (through Essence Parent Inc. and MergerCo) expired on June 15, 2026. This represents a material milestone in the completion of a change-of-control transaction, with the Company surviving as a wholly-owned subsidiary of Parent. The disclosure explicitly references the Merger Agreement entered into on May 1, 2026, and notes that stockholder approval remains a closing condition, with the special meeting scheduled for July 8, 2026.","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7832,"accession_number":"0001104659-26-074558","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that the HSR waiting period for the previously announced merger between Esperion and ArchiMed SAS (through Essence Parent Inc. and MergerCo) expired on June 15, 2026. This represents a material milestone in the completion of a change-of-control transaction, with the Company surviving as a wholly-owned subsidiary of Parent. The disclosure explicitly references the Merger Agreement entered into on May 1, 2026, and notes that stockholder approval remains a closing condition, with the special meeting scheduled for July 8, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:02:16.285425+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7832,"accession_number":"0001104659-26-074558","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that the HSR waiting period for the previously announced merger between Esperion and ArchiMed SAS (through Essence Parent Inc. and MergerCo) expired on June 15, 2026. This represents a material milestone in the completion of a change-of-control transaction, with the Company surviving as a wholly-owned subsidiary of Parent. The disclosure explicitly references the Merger Agreement entered into on May 1, 2026, and notes that stockholder approval remains a closing condition, with the special meeting scheduled for July 8, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T20:02:16.285425+00:00","company_name":"Esperion Therapeutics, Inc.","ticker":"ESPR","filing_date":"2026-06-16"}]}